This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alkermes to Buy Elan Unit for $960M

Updated with new information throughout.

WALTHAM, Massachusetts ( TheStreet) -- Alkermes (ALKS - Get Report) reached a deal to acquire Elan Drug Technologies from Elan (ELN), the Irish drugmaker, for $960 million in cash and stock.

Alkermes and Elan Drug Technologies will be combined under a new holding company headquartered in Ireland. The company will be named Alkermes Plc. and is expected to have annual revenue of more than $450 million from 25 commercialized products. Elan will have a 25% stake in the new company.

The deal joins two companies whose primary business focuses on technologies that improve the delivery of drugs made and sold by other companies. Elan Drug Technologies (EDT) formulates the once-monthly schizophrenia drug Invega Sustena sold by Johnson & Johnson (JNJ - Get Report) and Acorda Therapeutics' (ACOR - Get Report) multiple sclerosis medicine Ampyra. EDT generated $261 million in revenue last year, according to Bloomberg.

Alkermes is the drug-delivery technology partner for the once-weekly diabetes drug Bydureon under development by Eli Lilly (LLY) and Amylin Pharmaceuticals (AMLN). The current Alkermes is expected to record $181 million in revenue in the fiscal year ended March 31, most of which comes from royalties derived from Risperdal Consta, another schizophrenia drug marketed by J&J. More recently, Alkermes has started to develop and market its own drugs, including Vivitrol, used to combat alcohol and opioid dependence.

Alkermes loses money today but will turn cash-flow positive and profitable with the acquisition of the EDT business," the company said. On a pro forma basis, revenues are expected to grow in fiscal year 2012 with adjusted earnings in the range of $70 million to $90 million.

The new Alkermes will be led by current Alkermes chief executive Richard Pops. Shane Cooke, currently executive vice president and head of EDT, will join Alkermes as president.

"Both companies have a proven track record as innovators. This merger will bring the scale and resources for strategic and balanced investment across the whole product continuum, from R&D innovation to clinical development, to world-class manufacturing and commercial expansion. We're looking forward to working with the EDT team to accelerate growth and to create value for our shareholders and the patients we serve," said Pops, in a statement.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ELN $0.00 0.00%
ALKS $62.26 0.00%
ACOR $33.12 0.00%
JNJ $101.08 0.00%
AAPL $130.28 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs